Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource, 1 online resource.
Language
Englisch

Bibliographic citation
Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia ; volume:23 ; number:1 ; day:26 ; month:5 ; year:2023 ; pages:1-9 ; date:12.2023
BMC health services research ; 23, Heft 1 (26.5.2023), 1-9, 12.2023

Creator
Alharbi, Mansour A.
Aldosari, Fahad
Althobaiti, Ahmed Hasan
Abdullah, Faris M.
Aljarallah, Salman
Alkhawajah, Nuha M.
Alanazi, Miteb
AlRuthia, Yazed
Contributor
SpringerLink (Online service)

DOI
10.1186/s12913-023-09462-z
URN
urn:nbn:de:101:1-2023091108244366497257
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:57 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Alharbi, Mansour A.
  • Aldosari, Fahad
  • Althobaiti, Ahmed Hasan
  • Abdullah, Faris M.
  • Aljarallah, Salman
  • Alkhawajah, Nuha M.
  • Alanazi, Miteb
  • AlRuthia, Yazed
  • SpringerLink (Online service)

Other Objects (12)

Relapsing/remitting type 1 diabetes

Relapsing/remitting type 1 diabetes

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis

Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

Endocarditis following ocrelizumab in relapsing-remitting MS

Endocarditis following ocrelizumab in relapsing-remitting MS

Postural Control in Relapsing-Remitting Multiple Sclerosis

Postural Control in Relapsing-Remitting Multiple Sclerosis

Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report

Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab

Related objects